McKesson (MCK) · Health Care
McKesson Q2 FY2027 earnings: summary, key numbers & outlook
Results filed 4 Nov 2026 · Quarter ended 30 Sep 2026
Slides (32 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
McKesson deepened its push into specialty and oncology care, extending its CVS Health distribution deal through June 2032 and agreeing to a roughly 49% stake in Option Care Health.
McKesson extended its pharmaceutical distribution partnership with CVS Health through June 2032. Growth came from specialty products sold to health systems and strategic accounts, and from provider solutions and specialty distribution in Oncology & Multispecialty. Prescription Technology Solutions grew on third-party logistics and access solutions, though hub dispensing contributed less. In Medical-Surgical Solutions, a weaker product mix in ambulatory care held back profit. PRISM Vision Group added Spectrum Vision Partners, bringing its network to more than 350 providers.
Management is steering toward complex specialty therapies, community-based care and biopharma services. It signed a deal to invest about $1.4 billion for roughly 49% of Option Care Health and completed the Precision Medicine Group acquisition. It is also pursuing a separation of Medical-Surgical Solutions. The main risk is execution: the Option Care Health deal needs stockholder and regulatory approvals, and the separation and acquisitions may not deliver the intended benefits or hit the planned timelines.
Slides & documents
Open the slide deck (PDF, 32 pages) ↗
Showing the first 6 of 32 pages.
From McKesson investor relations
SEC filing
Key numbers
- Revenue · GAAP
- $111.0 billion
- Net income attributable to McKesson · GAAP
- $1.2B
- Diluted EPS · GAAP
- $10.44
- Adjusted diluted EPS · non-GAAP
- $11.68
- Operating income · GAAP
- 1.6B
- Operating cash flow · GAAP
- $3.1 billion
- Free cash flow · non-GAAP
- $2.9 billion
up 8% from a year ago
up 10% from a year ago
up $1.52 from a year ago
up 18% from a year ago
up 14% from a year ago
| Segment or metric | Value | Change |
|---|---|---|
| North American Pharmaceutical revenue | $91.4 billion | up 6% |
| Oncology & Multispecialty revenue | $15.0 billion | up 24% |
| Prescription Technology Solutions revenue | $1.5 billion | up 10% |
| Medical-Surgical Solutions revenue | $3.1 billion | up 5% |
Where each number comes from
- Revenue: “Second quarter revenues were $111.0 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes”
- Net income attributable to McKesson: “Net income attributable to McKesson Corporation | $1,218 | $1,110 | 10% | $1,832 | $1,894 | (3)%”
- Diluted EPS: “Second quarter earnings per diluted share was $10.44 compared to $8.92 a year ago, an increase of $1.52.”
- Adjusted diluted EPS: “Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86 a year ago, an increase of 18%”
- Operating income: “Operating income | 1,604 | 1,407 | 14 | 2,923 | 2,443 | 20 Other income (expense), net | 63 | 62 | 2”
- Operating cash flow: “During the three months ended September 30, 2026, McKesson generated cash from operations of $3.1 billion, and invested $123 million in capital expenditures”
- Free cash flow: “invested $123 million in capital expenditures, resulting in Free Cash Flow of $2.9 billion.”
- North American Pharmaceutical revenue: “Revenues were $91.4 billion, an increase of 6%, driven by increased prescription transaction volumes, including higher volumes from specialty products to health systems and strategic accounts”
- Oncology & Multispecialty revenue: “Revenues were $15.0 billion, an increase of 24%, driven by growth in provider solutions and specialty distribution.”
- Prescription Technology Solutions revenue: “Revenues were $1.5 billion, an increase of 10%, driven by increased prescription volumes in third-party logistics and access solutions”
- Medical-Surgical Solutions revenue: “Revenues were $3.1 billion, an increase of 5%, driven by growth across the extended and ambulatory care channels.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 FY2027 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $111.0B | +7.6% | +5.3% |
| Operating income | $1.6B | +14.0% | +21.6% |
| Net income | $1.2B | +9.7% | +98.4% |
| Diluted EPS | $10.44 | +17.0% | +102.7% |
| Free cash flow | $3.0B | +29.9% | — |
| Gross margin | 3.6% | +0.2 pts | +0.1 pts |
| Operating margin | 1.4% | +0.0 pts | +0.1 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Adjusted EPS | fiscal 2027 | $45.60 to $46.40 |
| Revenue growth | fiscal 2027 | 6% to 10% growth |
| Effective tax rate | fiscal 2027 | 18% to 19% |
| Free cash flow | fiscal 2027 | $4.5 to $4.9 billion |
Key takeaways
CVS Health distribution partnership extended to 2032
McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032. This secures a long-running anchor customer relationship.
McKesson is taking a 49% stake in Option Care Health
It signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health. The deal targets complex specialty therapies and community-based care, but still needs stockholder and regulatory approvals.
Precision Medicine Group acquisition expands biopharma services
McKesson completed the acquisition of Precision Medicine Group on November 2, 2026. The company calls it a milestone for its oncology, multispecialty and biopharma services strategy.
Oncology & Multispecialty is the fastest-growing segment
Segment revenue rose 24% on provider solutions and specialty distribution, and management lifted full-year revenue growth expectations to 20.0% to 24.0%. Management says it is making focused investments to accelerate this and biopharma services.
Medical-Surgical separation proceeds amid ambulatory mix pressure
McKesson is planning to separate Medical-Surgical Solutions, in which Apollo Funds acquired about a 13% minority stake. Segment profit fell 10% as ambulatory care mix weakened, partly offset by extended care.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q3 FY25 | $95.3B |
| Q4 FY25 | $90.8B * |
| Q1 FY26 | $97.8B |
| Q2 FY26 | $103.2B |
| Q3 FY26 | $106.2B |
| Q4 FY26 | $96.3B * |
| Q1 FY27 | $105.4B |
| Q2 FY27 | $111.0B |
Data
| Q3 FY25 | $6.95 |
| Q1 FY26 | $6.25 |
| Q2 FY26 | $8.92 |
| Q3 FY26 | $9.59 |
| Q1 FY27 | $5.15 |
| Q2 FY27 | $10.44 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q3 FY25 | 1.3% |
| Q4 FY25 | 1.8% |
| Q1 FY26 | 1.1% |
| Q2 FY26 | 1.4% |
| Q3 FY26 | 1.5% |
| Q4 FY26 | 2.2% |
| Q1 FY27 | 1.3% |
| Q2 FY27 | 1.4% |
Data
| Q3 FY25 | -$2.5B |
| Q4 FY25 | $7.6B |
| Q1 FY26 | -$1.0B |
| Q2 FY26 | $2.3B |
| Q3 FY26 | $1.1B |
| Q4 FY26 | $3.3B |
| Q1 FY27 | -$332.0M |
| Q2 FY27 | $3.0B |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is McKesson's strategic deal with Option Care Health?
McKesson agreed to invest about $1.4 billion for roughly 49% of Option Care Health, supporting complex specialty therapies and community-based care. It needs Option Care Health stockholder approval and regulatory approvals.
What happened with McKesson's CVS Health relationship?
McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
What is driving growth in McKesson's oncology business?
Oncology & Multispecialty revenue rose 24% on growth in provider solutions and specialty distribution. McKesson also completed the Precision Medicine Group acquisition to advance oncology, multispecialty and biopharma services.
What is happening to Medical-Surgical Solutions?
McKesson plans to separate it into an independent company, and Apollo Funds acquired about a 13% minority stake. Revenue grew 5%, but adjusted profit fell 10% on weaker ambulatory care mix.
How did McKesson raise its full-year outlook?
It raised fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00, and lifted its revenue and operating profit growth ranges. Its segment outlooks for North American Pharmaceutical and Oncology & Multispecialty were also raised.
Call recording
Call recording on YouTube ↗. Official replay ↗.





